drugset / Trial / NCT06924424
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of a three drug combination therapy of aponermin, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma
Timeline
- Start
- 2025-03-01
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aponermin | Unknown | 10 mg/kg | Intravenous |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |